Yizhou Dong

Yizhou Dong
Professional Website

Yizhou Dong, PhD

Associate Professor
Pharmaceutics and Pharmacology
434 Riffe Building
dong.525@osu.edu
(614) 292-3771

Professional Interests

Our research is devoted to drug discovery and development for the treatment of cancer as well as inherited genetic disorders. We integrate our specialty in pharmaceutics, pharmaceutical chemistry, biomedical engineering, materials formulation, and animal studies to design novel therapeutic medicines and uncover their mechanisms of actions. The ultimate goal is to translate our scientific results and technological inventions into more effective treatment and more fulfilling lives for all individuals.

Education

  • 2014, Postdoctoral Fellow, Massachusetts Institute of Technology & Harvard Medical School
  • 2009, PhD, University of North Carolina at Chapel Hill, Medicinal and Pharmaceutical Chemistry (MS, PhD),
  • 2005, MS, Shanghai Institute of Organic Chemistry, Organic Chemistry
  • 2002, BS, Peking University, Pharmaceutical Science
  • Certificate in Applied Biostatistics, Harvard Medical School
  • Teaching Certificate, Teaching and Learning Laboratory Massachusetts Institute of Technology

Honors

  • NIGMS-Maximizing Investigators' Research Award (MIRA), 2016 - 2021
  • New Investigator Grant, 2016 - 2017
  • Research Project Award, 2016 - 2017
  • Early Career Investigator Award, 2015 - 2017
  • ResearchReward, 2015 - 2016
  • Postdoctoral Fellow Awards, 2014
  • Ruth L. Kirschstein NRSA Postdoctoral Fellowship, 2013 - 2014
  • Postdoctoral Fellowship, 2013 - 2013
  • Graduate Student Award in Drug Design and Discovery, 2009 - 2009
  • The Rho Chi Pharmacy Honor Society, 2009 - 2009
  • Graduate Travel Award, 2009 - 2009
  • Beijing Outstanding Graduates, 2002 - 2002
  • Beijing Outstanding Undergraduate Students, 1999 - 1999
  • Fellowship of Peking University, 1998 - 2002

Journal Articles

  • Li B, Niu Y, Ji W, Dong Y. Strategies for the CRISPR-Based Therapeutics. Trends Pharmacol Sci. 2020 Jan;41(1):55-65.
  • Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020 Sep;10(9):1589-1600.
  • Hou X, Zhang X, Zhao W, Zeng C, Deng B, McComb DW, Du S, Zhang C, Li W, Dong Y. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat Nanotechnol. 2020 Jan;15(1):41-46.
  • Zeng C, Zhang C, Walker PG, Dong Y. Formulation and Delivery Technologies for mRNA Vaccines. Curr Top Microbiol Immunol. 2020 Jun 2.
  • Li B, Yan J, Zhang Y, Li W, Zeng C, Zhao W, Hou X, Zhang C, Dong Y. CRISPR- Cas12a Possesses Unconventional DNase Activity that Can Be Inactivated by Synthetic Oligonucleotides. Mol Ther Nucleic Acids. 2020 Mar 6;19:1043-1052.
  • Zhang S, Shrestha CL, Wisniewski BL, Pham H, Hou X, Li W, Dong Y, Kopp BT. Consequences of CRISPR-Cas9-Mediated CFTR Knockout in Human Macrophages. Front Immunol. 2020 Aug 18;11:1871.
  • Zhao P, Hou X, Yan J, Du S, Xue Y, Li W, Xiang G, Dong Y. Long-term storage of lipid-like nanoparticles for mRNA delivery. Bioact Mater. 2020 Mar 18;5(2):358-363.
  • Guo S, Vieweger M, Zhang K, Yin H, Wang H, Li X, Li S, Hu S, Sparreboom A, Evers BM, Dong Y, Chiu W, Guo P. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. Nat Commun. 2020 Feb 20;11(1):972.
  • Zeng C, Hou X, Yan J, Zhang C, Li W, Zhao W, Du S, Dong Y. Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo. Adv Mater. 2020 Oct;32(40):e2004452.
  • Zhang X, Zhao W, Nguyen GN, Zhang C, Zeng C, Yan J, Du S, Hou X, Li W, Jiang J, Deng B, McComb DW, Dorkin R, Shah A, Barrera L, Gregoire F, Singh M, Chen D, Sabatino DE, Dong Y. Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci Adv. 2020 Aug 21;6(34):eabc2315.
  • Hou X, Zhang X, Zhao W, Zeng C, Deng B, McComb DW, Du S, Zhang C, Li W, Dong Y. Author Correction: Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat Nanotechnol. 2020 Jul;15(7):615.
  • Li W, Chan C, Zeng C, Turk R, Behlke MA, Cheng X, Dong Y. Rational Design of Small Molecules to Enhance Genome Editing Efficiency by Selectively Targeting Distinct Functional States of CRISPR-Cas12a. Bioconjug Chem. 2020 Mar 18;31(3):542-546.
  • Li B, Zhang X, Dong Y. Nanoscale platforms for messenger RNA delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 May 04;:e1530.
  • Li B, Zeng C, Dong Y. Design and assessment of engineered CRISPR-Cpf1 and its use for genome editing. Nat Protoc. 2018 May;13(5):899-914.
  • Guo S, Li H, Ma M, Fu J, Dong Y, Guo P. Size, Shape, and Sequence-Dependent Immunogenicity of RNA Nanoparticles. Mol Ther Nucleic Acids. 2017 Dec 15;9:399-408.
  • Zhang X, Chen X, Zhao W, Zeng C, Luo X, Li W, Li B, Jiang J, Dong Y. GlcNAc Conjugated Atorvastatin with Enhanced Water Solubility and Cellular Internalization. Bioconjug Chem. 2017 08 16;28(8):2109-2113.
  • Zhang X, Li B, Luo X, Zhao W, Jiang J, Zhang C, Gao M, Chen X, Dong Y. Biodegradable Amino-Ester Nanomaterials for Cas9 mRNA Delivery in Vitro and in Vivo. ACS Appl Mater Interfaces. 2017 Aug 02;9(30):25481-25487.
  • Li B, Zhao W, Luo X, Zhang X, Li C, Zeng C, Dong Y. Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency. Nat Biomed Eng. 2017 May;1(5).
  • Jiang C, Mei M, Li B, Zhu X, Zu W, Tian Y, Wang Q, Guo Y, Dong Y, Tan X. A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo. Cell Res. 2017 Mar;27(3):440-443.
  • Li B, Dong Y. Preparation and Optimization of Lipid-Like Nanoparticles for mRNA Delivery. Methods Mol Biol. 2017;1632:207-217.
  • Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, Jordan CT, Dong Y. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. Bioorg Med Chem. 2016 11 15;24(22):5855-5860.
  • Dong Y, Wang W, Veiseh O, Appel EA, Xue K, Webber MJ, Tang BC, Yang XW, Weir GC, Langer R, Anderson DG. Injectable and Glucose-Responsive Hydrogels Based on Boronic Acid-Glucose Complexation. Langmuir. 2016 08 30;32(34):8743-7.
  • Li B, Luo X, Dong Y. Effects of Chemically Modified Messenger RNA on Protein Expression. Bioconjug Chem. 2016 Mar 16;27(3):849-53.
  • Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J, Suresh S, Bizhanova A, Gupta A, Bolukbasi MF, Walsh S, Bogorad RL, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe SA, Langer R, Xue W, Anderson DG. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016 Mar;34(3):328-33.
  • Li B, Luo X, Deng B, Giancola JB, McComb DW, Schmittgen TD, Dong Y. Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA. Sci Rep. 2016 Feb 26;6:22137.
  • Li B, Luo X, Deng B, Wang J, McComb DW, Shi Y, Gaensler KM, Tan X, Dunn AL, Kerlin BA, Dong Y. An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano Lett. 2015 Dec 09;15(12):8099-107.